Verastem (VSTM +0.2%) says a subject with platinum-resistant ovarian cancer realized a complete...

|About: Verastem (VSTM)|By:, SA News Editor

Verastem (VSTM +0.2%) says a subject with platinum-resistant ovarian cancer realized a complete response in an ongoing trial of a defactinib/ paclitaxel combo treatment. The patient's CA-125 level normalized after one cycle and "has remained at normal levels since," the company says. (PR)